Becton, Dickinson and Company has completed the acquisition of Waters, ahead of schedule, unlocking significant value for shareholders. The company will receive a $4 billion cash distribution, with $2 billion allocated for share repurchases and $2 billion for debt paydown. This transaction marks a pivotal moment in the company’s growth strategy, focusing on high-growth markets and innovation.

The company has entered a new chapter as a pure-play medtech company, focusing on smart connected devices, robotics, AI, and informatics, shifting care to lower-cost settings, and addressing rapid growth in technologies for chronic diseases. Becton, Dickinson and Company is positioned to lead in advancing the future of care with over 90% market presence and revenue from recurring consumables in over 190 countries.

In the first quarter, the company saw solid revenue growth of 0.4% with strong performance in Medical Essentials, Vascular Access Management, and Connected Care. Despite headwinds in Life Sciences and VDB, the company delivered strong competitive wins, increased market share, and continued growth in strategic areas like biopharma systems and interventional solutions. Adjusted gross margin was 53.4%, impacted by tariffs, while adjusted EPS was $2.91, exceeding expectations.

Looking ahead, Becton, Dickinson and Company aims to achieve low single-digit revenue growth in fiscal 2026, with currency as a tailwind. The company continues its focus on delivering innovative solutions to the market, leveraging its strong innovation pipeline and commercial capabilities to drive growth. With a balanced capital allocation strategy, including tuck-in M&A, the company is poised for continued success in the evolving healthcare landscape.

Read more at Yahoo Finance: Becton Dickinson BDX Q1 2026 Earnings Transcript